Xeno Transplants Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XENO research report →
About the company
Xeno Transplants Corporation functions as a biotechnology firm dedicated to research and development. Leveraging a specific licensing agreement with Massachusetts General Hospital, the company aims to innovate, produce, commercialize, and implement products and methodologies for public application in the field of xenotransplantation. The primary objective of this xenotransplantation research is to alleviate the critical scarcity of human cells, tissues, and organs required for medical transplants.
- CEO
- Elliot Lebowitz
- IPO
- 2006
- HQ
- Brookline, MA, US
Price Chart
- Market Cap
- $4.04K
- P/E
- -0.03
- P/S
- 0.00
- P/B
- 0.01
- EV/EBITDA
- 0.22
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -68.64%
- ROIC
- 33.21%
- Revenue
- $0 · 0.00%
- Net Income
- $-128,185 · -174.74%
- EPS
- $-0.00 · 61.00%
- Op Income
- $128.19K
- FCF YoY
- -1909.55%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -28.50
- Avg Volume
- 161
Get TickerSpark's AI analysis on XENO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our XENO coverage
Recent articles, reports, and earnings notes.
No research on XENO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate XENO report →Similar companies
Peers in the same neighborhood.